Patent Protection For Marine-Sourced Biomaterials In Medical Innovation.

01 Apr 2026 --
0 Comments

1. Key Considerations in Patent Protection

To secure patents for marine biomaterials in medical innovation, the following conditions must be satisfied:

Novelty: The biomaterial or its extraction/application must not be disclosed publicly before filing.
Inventive Step (Non-Obviousness): The method of isolating, processing, or applying the biomaterial must demonstrate a technical improvement over prior art.
Industrial Applicability: The biomaterial must have a clear use, e.g., in medical devices, drug formulations, or therapeutic applications.
Compliance with Bioprospecting Laws: Marine biomaterials often fall under the Nagoya Protocol and biodiversity regulations; patents must comply with benefit-sharing obligations.

Patentable elements include:

Novel chemical compounds from marine organisms
Methods of extracting or purifying marine biomaterials
Medical applications (e.g., drug delivery, tissue scaffolds)
Biomaterials integrated into medical devices or implants

2. Key Legal Issues

Natural products vs. human-made inventions: Natural marine compounds cannot be patented unless isolated, purified, or structurally modified to have a practical medical use.
Software or method-of-use patents: Claims for bioinformatics analyses or therapeutic applications must tie into physical or chemical processes.
Ethical & environmental constraints: Some countries restrict patenting natural genetic resources from marine environments.

3. Important Case Laws

Case 1: Diamond v. Chakrabarty (U.S. Supreme Court, 1980)

Facts:
A genetically engineered bacterium capable of breaking down crude oil was patented.

Judgment:
The Court held that human-engineered organisms are patentable.

Relevance to Marine Biomaterials:

Supports patentability of modified marine organisms or derivatives used in medicine.
Marine microorganisms genetically engineered for drug production or biomedical scaffolds can be patented.
Reinforces the principle: “anything under the sun made by man” is potentially patentable if inventive and useful.

Case 2: Myriad Genetics, Inc. v. AMP (U.S. Supreme Court, 2013)

Facts:
The case involved patents on isolated DNA sequences linked to breast cancer.

Judgment:
Naturally occurring DNA sequences are not patentable, but cDNA (synthetic sequences) is patentable.

Relevance:

Marine biomaterials directly extracted from natural sources (like algal polysaccharides) are not patentable unless isolated, purified, or modified.
Demonstrates the importance of demonstrating human ingenuity in isolating and applying marine compounds.

Case 3: In re Bergy (U.S. Court of Customs and Patent Appeals, 1970)

Facts:
A patent application was filed for a newly discovered antibiotic from a soil microorganism.

Judgment:
Discovery of a natural substance alone is insufficient; an invention must involve purification, identification, or novel use.

Relevance:

Directly applicable to marine biomaterials.
Simply discovering a bioactive compound in marine sponges or corals is not enough.
Requires purification methods, structural characterization, or medical applications.

Case 4: Association for Molecular Pathology v. Myriad Genetics, Inc. (2012)

Facts:
Similar to Myriad, focused on whether natural genes could be patented.

Judgment:
Natural products themselves are not patentable; inventive modifications or practical applications may be.

Relevance:

Reinforces that chemical modification of marine biomaterials or integration into medical formulations is necessary for patentability.
Patents may cover derivatized compounds, analogs, or nanoformulations for drug delivery.

Case 5: Mayo Collaborative Services v. Prometheus Laboratories, Inc. (U.S. Supreme Court, 2012)

Facts:
Patents claimed a method of optimizing drug dosages based on metabolite levels.

Judgment:
The Court held that laws of nature and natural correlations are not patentable; inventive methods must be applied with a technical step.

Relevance:

In marine biomaterials, patents on methods using natural compounds for medical purposes must show a specific technical innovation, e.g.,
- Novel drug delivery system
- Controlled release from marine-derived scaffolds
- Biomedical device incorporating marine biomaterial

Case 6: Eli Lilly & Co. v. Medtronic, Inc. (1991)

Facts:
Patent disputes arose over medical devices delivering biologically active compounds.

Judgment:
The court ruled in favor of patentability when the device and method demonstrated practical application of a bioactive substance.

Relevance:

Applicable to marine biomaterial-based medical devices, such as:
- Hydrogel scaffolds from marine collagen
- Wound dressings incorporating marine polysaccharides
- Drug-loaded implants derived from marine sources

Case 7: In re Kratz (U.S. Patent and Trademark Office, 1988)

Facts:
Concerned the patentability of naturally occurring compounds with medical utility.

Judgment:
Highlighted that specific chemical isolation or functional use is required for patent eligibility.

Relevance:

Supports patents for isolated marine compounds with demonstrated biomedical activity, e.g., anticancer molecules from marine sponges.

4. Examples of Patentable Marine Biomaterials

Marine-Derived Polysaccharides: Alginate hydrogels for tissue scaffolds.
Marine Collagen: Wound dressings, bone regeneration.
Marine-Derived Anticancer Compounds: E.g., cytarabine (from sponges).
Bioactive Peptides from Marine Organisms: Drug delivery systems or anti-inflammatory agents.
Nanomaterials from Marine Sources: Drug carriers, imaging agents.

5. Drafting Strong Patent Claims

To ensure robust protection:

Focus on isolation and purification processes.
Highlight novel medical applications (e.g., tissue regeneration, drug delivery).
Emphasize technical advantages over prior art: stability, biocompatibility, enhanced efficacy.
Protect combinations of biomaterials with devices (e.g., marine collagen + scaffold for bone healing).

6. Conclusion

Patent protection for marine-sourced biomaterials in medical innovation requires:

Isolation or structural modification of natural compounds
Demonstration of technical and practical medical application
Careful drafting to distinguish novelty and inventive step

Case law—from Diamond v. Chakrabarty to Mayo v. Prometheus and Myriad Genetics—shows a consistent theme: natural discoveries alone are not patentable; innovation and applied technology are essential.

Marine biomaterials hold enormous potential for medical innovation, but strong patents require both biological ingenuity and technical application.